At the 14th St. Gallen International Breast Cancer Conference 2015, Masakazu Toi, MD, PhD, of Kyoto University, Japan, explains that there are still only limited data available regarding the genomic profile of breast tumours in Japanese patients.
Information gained from pathological assessment and multigene assays, such as the Oncotype DX® Breast Cancer Assay and MammaPrint™, needs to be compiled to further understand breast cancer as a disease and to determine how molecular profiling can be applied in the clinic.
In Japan, multigene assays for breast cancer are not currently part of the healthcare system. However, Dr Toi believes that these assays can be useful to predict prognosis in the presence of endocrine therapy and chemotherapy, and hopes that in the future it will be possible to access these assays more easily.
This content is supported by Genomic Health, Inc.